<DOC>
	<DOCNO>NCT01802489</DOCNO>
	<brief_summary>Optic neuritis ( ON ) common event Multiple Sclerosis ( MS ) , cause significant loss nerve cell eye , result poor vision . Optic neuritis also provide sensitive way test effectiveness drug may help protect loss nerve cell ON therefore MS . The investigator identify laboratory early clinical research human amiloride ( water tablet already use ) may drug benefit optic neuritis protect loss nerve cell , ie neuroprotective drug . The purpose study assess efficacy amiloride neuroprotective drug optic neuritis</brief_summary>
	<brief_title>Amiloride Clinical Trial In Optic Neuritis</brief_title>
	<detailed_description>Multiple sclerosis ( MS ) , inflammatory condition nervous system , common cause disability people work age western world . In addition inflammatory episode MS , axonal neuronal damage occur . It axonal loss think major pathological substrate disability MS . Acute inflammatory demyelinate optic neuritis common event multiple sclerosis . Following optic neuritis axonal loss optic nerve retina , severe result poor visual recovery . Uniquely amongst central nervous system ( CNS ) structure , structural functional change eye follow optic neuritis provide sensitive way observe neurodegeneration test effectiveness potential neuroprotective agent . In optic neuritis show thin retinal nerve fibre layer take place , 6 month thin establish largely stabilise . This represent axonal loss anterior visual system . The degree thin show correlate amount vision recover follow optic neuritis , thin occurs , poor outcome . The thickness retinal nerve fibre layer measure simple scan technique scan laser polarimetry ( GDx ) optical coherence tomography ( OCT ) . Axonal loss MS likely multifactorial , key end point influx sodium calcium ion . Recent research suggest inflammatory environment optic neuritis , acid sense ion channel may important role influx sodium calcium , therefore axonal loss MS . The drug amiloride , already use diuretic , know blocker ion channel . The investigator identify laboratory early clinical research human blockade acid sense ion channel , amiloride may neuroprotective optic neuritis MS . The investigator primary objective ass neuroprotective efficacy amiloride optic neuritis surrogate measure retinal nerve fibre layer measurement . Secondary objective assess marker neurodegeneration ON neuroprotective effect amiloride non-conventional MRI outcome , assess amiloride improve functional visual outcome follow optic neuritis , confirm optic neuritis sensitive efficient model neuroprotection clinical trial framework . 46 Participants recruit receive either amiloride , identical placebo capsule 5 month . The primary outcome measure 6 month , measure 12 month . Should trial show significant benefit amiloride optic neuritis , important first step develop neuroprotective therapy optic neuritis MS potentially could significant impact people MS carers .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Optic Neuritis</mesh_term>
	<mesh_term>Neuritis</mesh_term>
	<mesh_term>Amiloride</mesh_term>
	<criteria>Participants first episode unilateral optic neuritis Participants exist diagnosis relapse remit MS new onset ON eligible ; 1 . Not previous episode optic neuritis , 2 . A duration disease ≤10 year 3 . An EDSS ( Expanded Disability Status Scale ) ≤3 . 4 . No immune modulating treatment βInterferon glatiramer acetate time recruitment Able randomise within 28 day onset visual symptom Visual acuity ≤6/9 Participant willing able give inform consent participation study able comply study visit Male Female , age between18 55 year . Stable dose current regular medication least 4 week prior study entry . Participant clinically acceptable urea electrolyte estimate glomerular filtration rate ( eGFR ) &gt; 60 Able willing comply study requirement . Willing allow General Practitioner notify participation study . Previous diagnosis optic neuritis Any concomitant immune suppress immune modulate therapy exclude βinterferon glatiramer acetate . Female participant pregnant , lactate plan pregnancy course study . Concomitant potassium supplement , angiotensin convert enzyme inhibitor , angiotensin II antagonist , cyclosporine , tacrolimus lithium Any contraindication MRI severe claustrophobia , metal implant , pacemaker , etc . Participant terminally ill inappropriate placebo medication Impaired renal function : eGFR ≤60 , anuria , acute chronic renal insufficiency evidence diabetic nephropathy Raised serum potassium ( K+ &gt; 5.5mmol/l ) Diabetes Significant concomitant eye disease either eye may affect diseased fellow eye result . Any significant disease disorder , opinion investigator , may either put participant risk participation study , may influence result study , participant 's ability participate study . Participants participate another research study involve investigational product past 12 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Optic neuritis</keyword>
	<keyword>Multiple sclerosis</keyword>
	<keyword>Retinal nerve fibre layer</keyword>
	<keyword>Axonal loss</keyword>
	<keyword>Neuroprotection</keyword>
	<keyword>MRI</keyword>
	<keyword>Optical coherence tomography</keyword>
	<keyword>Amiloride</keyword>
	<keyword>Acid Sensing Ion Channels</keyword>
</DOC>